Health-Related Quality of Life in Advanced Non-small Cell Lung Cancer: A Methodological Appraisal Based on a Systematic Literature Review

被引:16
作者
Van Der Weijst, Lotte [1 ]
Lievens, Yolande [1 ]
Schrauwen, Wim [2 ]
Surmont, Veerle [3 ]
机构
[1] Ghent Univ Hosp, Dept Radiotherapy Oncol, Ghent, Belgium
[2] Ghent Univ Hosp, Dept Med Oncol, Ghent, Belgium
[3] Ghent Univ Hosp, Dept Thorac Oncol, Ghent, Belgium
来源
FRONTIERS IN ONCOLOGY | 2019年 / 9卷
关键词
quality of life; review-systematic; lung cancer; methodological quality; NSCLC; RANDOMIZED PHASE-III; DOCETAXEL PLUS CISPLATIN; COMPREHENSIVE GERIATRIC ASSESSMENT; PATIENT-REPORTED OUTCOMES; COMPARING PACLITAXEL POLIGLUMEX; GEFITINIB MAINTENANCE THERAPY; PLATINUM-BASED CHEMOTHERAPY; TREATED JAPANESE PATIENTS; SINGLE-AGENT GEMCITABINE; ELDERLY-PATIENTS;
D O I
10.3389/fonc.2019.00715
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The majority of lung cancer patients are diagnosed with advanced non-small cell lung cancer (NSCLC), the bulk of which receive palliative systemic treatment with the goal to provide effective symptom palliation and safeguard health-related quality of life (HRQoL). Advanced NSCLC trials with HRQoL endpoints face methodological constraints limiting interpretability. Objectives: We provide a comprehensive overview of recent clinical trials evaluating the impact of systemic therapies on HRQoL in advanced NSCLC, focusing on the methodological quality, with the ultimate goal to improve interpretation, comparison and reporting of HRQoL data. Methods: A systematic literature review was performed. Prospective studies published over the last decade evaluating the impact of systemic treatments on HRQoL in advanced NSCLC were included. Methodological quality of HRQoL reporting was assessed with the CONSORT-PRO extension. Results: Hundred-twelve manuscripts describing 85 trials met all criteria. No formal conclusion can be drawn regarding the impact on HRQoL of different treatments. We report an important variety in methodological quality in terms of definitions of HRQoL, missing data points, lack of standardization of analyzing and presenting HRQoL and no standard follow-up time. The quality of HRQoL data reporting varies substantially between studies but improves over time. Conclusion: This review shows that in the heterogeneous landscape of trials addressing HRQoL in advanced stage NSCLC. Methodology reporting remains generally poor. Adequate reporting of HRQoL outcome data is equally important to support clinical decision-making as to correctly inform health policy regarding direct approval and reimbursement of the new drugs and combinations that will come online.
引用
收藏
页数:13
相关论文
共 149 条
[1]   Randomized Phase III Trial Comparing Weekly Docetaxel Plus Cisplatin Versus Docetaxel Monotherapy Every 3 Weeks in Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Intergroup Trial JCOG0803/WJOG4307L [J].
Abe, Tetsuya ;
Takeda, Koji ;
Ohe, Yuichiro ;
Kudoh, Shinzoh ;
Ichinose, Yukito ;
Okamoto, Hiroaki ;
Yamamoto, Nobuyuki ;
Yoshioka, Hiroshige ;
Minato, Koichi ;
Sawa, Toshiyuki ;
Iwamoto, Yasuo ;
Saka, Hideo ;
Mizusawa, Junki ;
Shibata, Taro ;
Nakamura, Shinichiro ;
Ando, Masahiko ;
Yokoyama, Akira ;
Nakagawa, Kazuhiko ;
Saijo, Nagahiro ;
Tamura, Tomohide .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (06) :575-U65
[2]   A new frontier for targeted therapy in NSCLC: clinical efficacy of pembrolizumab in the inhibition of programmed cell death 1 (PD-1) [J].
Addeo, Raffaele .
EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (03) :199-201
[3]   Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study CALGB 30607 (Alliance) [J].
Baggstrom, Maria Q. ;
Socinski, Mark A. ;
Wang, Xiaofei F. ;
Gu, Lin ;
Stinchcombe, Thomas E. ;
Edelman, Martin J. ;
Baker, Sherman, Jr. ;
Feliciano, Josephine ;
Novotny, Paul ;
Hahn, Olwen ;
Crawford, Jeffrey A. ;
Vokes, Everett E. .
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (05) :843-849
[4]   Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: AVAPERL (MO22089) [J].
Barlesi, Fabrice ;
Scherpereel, Arnaud ;
Rittmeyer, Achim ;
Pazzola, Antonio ;
Tur, Neus Ferrer ;
Kim, Joo-Hang ;
Ahn, Myung-Ju ;
Aerts, Joachim G. J. V. ;
Gorbunova, Vera ;
Vikstrom, Anders ;
Wong, Elaine K. ;
Perez-Moreno, Pablo ;
Mitchell, Lada ;
Groen, Harry J. M. .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (24) :3004-+
[5]   Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study [J].
Basch, Ethan ;
Iasonos, Alexia ;
McDonough, Tiffani ;
Barz, Allison ;
Culkin, Ann ;
Kris, Mark G. ;
Scher, Howard I. ;
Schrag, Deborah .
LANCET ONCOLOGY, 2006, 7 (11) :903-909
[6]   Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study [J].
Belani, Chandra P. ;
Brodowicz, Thomas ;
Ciuleanu, Tudor E. ;
Krzakowski, Maciej ;
Yang, Sung Hyun ;
Franke, Fabio ;
Cucevic, Branka ;
Madhavan, Jayaprakash ;
Santoro, Armando ;
Ramlau, Rodryg ;
Liepa, Astra M. ;
Visseren-Grul, Carla ;
Peterson, Patrick ;
John, William J. ;
Zielinski, Christoph C. .
LANCET ONCOLOGY, 2012, 13 (03) :292-299
[7]   Patient-reported outcome measures (PROMs) in the management of lung cancer: A systematic review [J].
Ben Bouazza, Youssef ;
Chiairi, Ibrahim ;
El Kharbouchi, Ouiam ;
De Backer, Lesley ;
Vanhoutte, Greetje ;
Janssens, Annelies ;
Van Meerbeeck, Jan P. .
LUNG CANCER, 2017, 113 :140-151
[8]   Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group study BR.21 [J].
Bezjak, Andrea ;
Tu, Dongsheng ;
Seymour, Lesley ;
Clark, Gary ;
Trajkovic, Aleksandra ;
Zukin, Mauro ;
Ayoub, Joseph ;
Lago, Sergio ;
de Albuquerque Ribeiro, Ronaldo ;
Gerogianni, Alexandra ;
Cyjon, Arnold ;
Noble, Jonathan ;
Laberge, Francis ;
Chan, Raymond Tsz-Tong ;
Fenton, David ;
von Pawel, Joachim ;
Reck, Martin ;
Shepherd, Frances A. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (24) :3831-3837
[9]   Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin-gemcitabine or carboplatin-paclitaxel: NVALT-3 a phase III study [J].
Biesma, B. ;
Wymenga, A. N. M. ;
Vincent, A. ;
Dalesio, O. ;
Smit, H. J. M. ;
Stigt, J. A. ;
Smit, E. F. ;
van Felius, C. L. ;
van Putten, J. W. G. ;
Slaets, J. P. J. ;
Groen, H. J. M. .
ANNALS OF ONCOLOGY, 2011, 22 (07) :1520-1527
[10]   Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients with ALK-Positive Advanced Non-Small-Cell Lung Cancer [J].
Blackhall, Fiona ;
Kim, Dong-Wan ;
Besse, Benjamin ;
Nokihara, Hiroshi ;
Han, Ji-Youn ;
Wilner, Keith D. ;
Reisman, Arlene ;
Iyer, Shrividya ;
Hirsh, Vera ;
Shaw, Alice T. .
JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (11) :1625-1633